Endometrial Mixed Cell Adenocarcinoma

subtype

Identifier: CI-CAN-00007647
Entity page: /cancer/endometrial-mixed-cell-adenocarcinoma ↗
Edges: 31

Neighbours: 15 drugs10 trials
Drawn: 25 of 25 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,149 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Endometrial Mixed Cell Adenocarcinoma investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 19show all (up to 200)
→ investigated in trials for	Carboplatinsmall molecule 2 trials (2 active) · roll-up of the cancer and its descendants	—	—	Endometrial Mixed Cell Adenocarcinoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Paclitaxel

Endometrial Mixed Cell Adenocarcinoma studied in …STUDIED_INderived10 of 12show all (up to 200)
→ studied in	NCT05112601Phase 2 · recruiting Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma · condition mapped ONTOLOGY_EXACT · 12 trials mapped (6 active)	—	—	Endometrial Mixed Cell Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05256225Phase 3 · recruiting Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma · condition mapped ONTOLOGY_EXACT · 12 trials mapped (6 active)	—	—	Endometrial Mixed Cell Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03660826Phase 2 · active not recruiting Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone · condition mapped ONTOLOGY_EXACT · 12 trials mapped (6 active)	—	—	Endometrial Mixed Cell Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03914612Phase 3 · active not recruiting Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer · condition mapped ONTOLOGY_EXACT · 12 trials mapped (6 active)	—	—	Endometrial Mixed Cell Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03120624Phase 1 · active not recruiting VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer · condition mapped CURATED_BROADER · 12 trials mapped (6 active)	—	—	Endometrial Mixed Cell Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04719273Phase 2 · completed Onapristone and Anastrozole for the Treatment of Refractory Hormone Receptor Positive Endometrial Cancer · condition mapped CURATED_BROADER · 12 trials mapped (6 active)	—	—	Endometrial Mixed Cell Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05542407Phase 1 · recruiting ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer · condition mapped ONTOLOGY_EXACT · 12 trials mapped (6 active)	—	—	Endometrial Mixed Cell Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT01935934Phase 2 · completed Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer · condition mapped ONTOLOGY_EXACT · 12 trials mapped (6 active)	—	—	Endometrial Mixed Cell Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02020707Phase 1 · completed Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers · condition mapped ONTOLOGY_EXACT · 12 trials mapped (6 active)	—	—	Endometrial Mixed Cell Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05390021NA · withdrawn PET/MRI in Endometrial Cancer · condition mapped ONTOLOGY_EXACT · 12 trials mapped (6 active)	—	—	Endometrial Mixed Cell Adenocarcinoma	1	Observed	clinicaltrials	graph →

Radial view

Every edge, grouped by relationship

Strongest chains